We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic (MDT) Beats on Q3 Earnings & Revenues Estimates
Read MoreHide Full Article
Are you a medical practitioner? Yes, then you must be aware of Minnesota-based one of the world’s leading medical technology giant – Medtronic plc (MDT - Free Report) which has a global reach that extends to more than 140 countries. Last year, more than 10 million people benefited from Medtronic’s medical therapies, which treat cardiac and vascular diseases, diabetes, and neurological and musculoskeletal conditions.
Currently, Medtronic has a Zacks Rank #4 (Sell) but that could change following its positive third-quarter fiscal 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings:The current Zacks Consensus Estimate stands at $1.11 per share. Medtronic’s adjusted earnings per share of $1.12 exceeded this estimate by 0.9%.
Revenues: Medtronic posted revenues of $7.28 billion, exceeding the Zacks Consensus Estimate for revenues of $7.23 billion.
Key Stats: Revenues from Medtronic’s Cardiac and Vascular Group rose 6% at Constant exchange Rate (CER) to $2.54 billion, while revenues from Minimally Invasive Therapies Group increased 6% at CER to $2.41 billion. On the other hand, revenues from Restorative Therapies Group rose 4% at CER to $1.81 billion, while revenues from Diabetes Group grew 7% at CER to $501 million.
Major Factors: Medtronic reported impressive third quarter fiscal 2017 results with both top-line and bottom-line exceeding the Zacks Consensus Estimate. The company’s year over year top line performance was also impressive across all business groups. The company however reiterated its FY17 guidance citing revenue, free cash flow and EPS outlook.
Stock Price: Following the earnings release, share prices rose almost 0.28% in the pre-market trading session.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? Last year's market-beating Top 10 portfolio produced 5 double-digit winners. For example, oil and natural gas giant Pioneer Natural Resources and First Republic Bank racked up stellar gains of +44.9% and +44.3% respectively. Now a brand-new list for 2017 has been hand-picked from 4,400 companies covered by the Zacks Rank. See the 2017 Top 10 right now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Medtronic (MDT) Beats on Q3 Earnings & Revenues Estimates
Are you a medical practitioner? Yes, then you must be aware of Minnesota-based one of the world’s leading medical technology giant – Medtronic plc (MDT - Free Report) which has a global reach that extends to more than 140 countries. Last year, more than 10 million people benefited from Medtronic’s medical therapies, which treat cardiac and vascular diseases, diabetes, and neurological and musculoskeletal conditions.
Currently, Medtronic has a Zacks Rank #4 (Sell) but that could change following its positive third-quarter fiscal 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings:The current Zacks Consensus Estimate stands at $1.11 per share. Medtronic’s adjusted earnings per share of $1.12 exceeded this estimate by 0.9%.
Medtronic PLC Price and EPS Surprise
Medtronic PLC Price and EPS Surprise | Medtronic PLC Quote
Revenues: Medtronic posted revenues of $7.28 billion, exceeding the Zacks Consensus Estimate for revenues of $7.23 billion.
Key Stats: Revenues from Medtronic’s Cardiac and Vascular Group rose 6% at Constant exchange Rate (CER) to $2.54 billion, while revenues from Minimally Invasive Therapies Group increased 6% at CER to $2.41 billion. On the other hand, revenues from Restorative Therapies Group rose 4% at CER to $1.81 billion, while revenues from Diabetes Group grew 7% at CER to $501 million.
Major Factors: Medtronic reported impressive third quarter fiscal 2017 results with both top-line and bottom-line exceeding the Zacks Consensus Estimate. The company’s year over year top line performance was also impressive across all business groups. The company however reiterated its FY17 guidance citing revenue, free cash flow and EPS outlook.
Stock Price: Following the earnings release, share prices rose almost 0.28% in the pre-market trading session.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? Last year's market-beating Top 10 portfolio produced 5 double-digit winners. For example, oil and natural gas giant Pioneer Natural Resources and First Republic Bank racked up stellar gains of +44.9% and +44.3% respectively. Now a brand-new list for 2017 has been hand-picked from 4,400 companies covered by the Zacks Rank. See the 2017 Top 10 right now>>